As of November 16, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Mentari Therapeutics, Inc. The largest reported stake is Vivo Opportunity Fund Holdings, L.P.'s, at 21.7%. 9 filings are on record since January 20, 2026 (Schedule 13D, June 10, 2026).
Sell to companies like Mentari Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 2,977,478 · Sole dispositive: 0 · Shared dispositive: 2,977,478 · SCHEDULE 13G, 2026-11-13
- · Reporting person: Commodore Capital LP · Sole voting: 0 · Shared voting: 2,977,630 · Sole dispositive: 0 · Shared dispositive: 2,977,630 · SCHEDULE 13G, 2026-11-13
- · Reporting person: Fairmount Funds Management LLC · Sole voting: 0 · Shared voting: 10,555,507 · Sole dispositive: 0 · Shared dispositive: 10,555,507 · SCHEDULE 13D, 2026-11-12
- · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 943,668 · Sole dispositive: 0 · Shared dispositive: 943,668 · SCHEDULE 13G/A, 2026-10-07
- · Reporting person: Ikarian Capital, LLC · Sole voting: 0 · Shared voting: 137,634 · Sole dispositive: 0 · Shared dispositive: 137,634 · SCHEDULE 13G, 2026-08-14
Mentari Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2026-01-20. 7 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-03-06 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 21.7% | 718,444 | SCHEDULE 13D, 2026-06-10 | 2026-05-19 |
| Fairmount Funds Management LLC | 19.99% | 10,555,507 | SCHEDULE 13D, 2026-11-12 | 2026-11-06 |
| ADAR1 Capital Management, LLC | 17.2% | 943,668 | SCHEDULE 13G/A, 2026-10-07 | 2026-09-30 |
| Sabby Management, LLC | 9.9% | 280,138 | SCHEDULE 13G, 2026-01-20 | 2025-12-31 |
| Squadron Master Fund LP | 9.8% | 325,000 | SCHEDULE 13G, 2026-05-27 | 2026-05-19 |
| Deep Track Capital, LP | 5.64% | 2,977,478 | SCHEDULE 13G, 2026-11-13 | 2026-11-06 |
| Commodore Capital LP | 5.6% | 2,977,630 | SCHEDULE 13G, 2026-11-13 | 2026-11-06 |
| Ikarian Capital, LLC | 4.2% | 137,634 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Mentari Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Mentari Therapeutics, Inc. and the records around it.
Mentari Therapeutics, Inc. elsewhere on the record
- Acquisition Nov 2026
- Leadership changes Nov 2026
- Layoff notices Mar 2026
- Who owns it
Companies that share a holder
- Fairmount Funds Management LLC also filed stake reports on 14 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Tempest Therapeutics, Inc. (Jan 2026)
Watch Mentari Therapeutics, Inc.
Get an email when Mentari Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Mentari Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Mentari Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mentari Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 718,444 | 0 | 718,444 | 0 | SCHEDULE 13D, 2026-06-10 |
| Vivo Opportunity, LLC | 718,444 | 0 | 718,444 | 0 | SCHEDULE 13D, 2026-06-10 |
| Vivo Opportunity Cayman Fund, L.P. | 72,535 | 0 | 72,535 | 0 | SCHEDULE 13D, 2026-06-10 |
| Vivo Opportunity Cayman, LLC | 72,535 | 0 | 72,535 | 0 | SCHEDULE 13D, 2026-06-10 |
| Fairmount Funds Management LLC | 0 | 10,555,507 | 0 | 10,555,507 | SCHEDULE 13D, 2026-11-12 |
| Fairmount Healthcare Fund II L.P. | 0 | 10,555,507 | 0 | 10,555,507 | SCHEDULE 13D, 2026-11-12 |
| Peter Evan Harwin | 0 | 10,555,507 | 0 | 10,555,507 | SCHEDULE 13D, 2026-11-12 |
| Tomas Kiselak | 0 | 10,555,507 | 0 | 10,555,507 | SCHEDULE 13D, 2026-11-12 |
| ADAR1 Capital Management, LLC | 0 | 943,668 | 0 | 943,668 | SCHEDULE 13G/A, 2026-10-07 |
| Daniel Schneeberger | 0 | 943,668 | 0 | 943,668 | SCHEDULE 13G/A, 2026-10-07 |
| Squadron Master Fund LP | 0 | 325,000 | 0 | 325,000 | SCHEDULE 13G, 2026-05-27 |
| Squadron Capital Management LLC | 0 | 325,000 | 0 | 325,000 | SCHEDULE 13G, 2026-05-27 |
| Matthew Sesterhenn | 0 | 325,000 | 0 | 325,000 | SCHEDULE 13G, 2026-05-27 |
| William Blank | 0 | 325,000 | 0 | 325,000 | SCHEDULE 13G, 2026-05-27 |
| Deep Track Capital, LP | 0 | 2,977,478 | 0 | 2,977,478 | SCHEDULE 13G, 2026-11-13 |
| Deep Track Biotechnology Master Fund, Ltd. | 0 | 2,214,135 | 0 | 2,214,135 | SCHEDULE 13G, 2026-11-13 |
| David Kroin | 0 | 2,977,478 | 0 | 2,977,478 | SCHEDULE 13G, 2026-11-13 |
| Deep Track Special Opportunities Fund, LP. | 0 | 763,343 | 0 | 763,343 | SCHEDULE 13G, 2026-11-13 |
| Commodore Capital LP | 0 | 2,977,630 | 0 | 2,977,630 | SCHEDULE 13G, 2026-11-13 |
| Commodore Capital Master LP | 0 | 2,977,630 | 0 | 2,977,630 | SCHEDULE 13G, 2026-11-13 |
| Robert Egen Atkinson | 0 | 2,977,630 | 0 | 2,977,630 | SCHEDULE 13G, 2026-11-13 |
| Michael Kramarz | 0 | 2,977,630 | 0 | 2,977,630 | SCHEDULE 13G, 2026-11-13 |
| Ikarian Capital, LLC | 0 | 137,634 | 0 | 137,634 | SCHEDULE 13G, 2026-08-14 |
| Neil Shahrestani | 0 | 137,634 | 0 | 137,634 | SCHEDULE 13G, 2026-08-14 |
The latest filing identifies Mentari Therapeutics, Inc. by CUSIP 587157108 and gives its principal executive office as 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (SCHEDULE 13G, 2026-11-13).
Source of funds (Item 3)
The funds used to purchase the securities reported herein came from the working capital of Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P.Vivo Opportunity Fund Holdings, L.P., SCHEDULE 13D, 2026-06-10
In aggregate, the Reporting Persons have voting and dispositive power over 10,555,507 shares of Common Stock, which is comprised of (a) 10,555,507 shares of Common Stock directly held by Fund II, and exclude (b) 4,013,000 shares of Common Stock issuable upon conversion of 4,013 shares of Series A Preferred Stock directly held by Fund II and 1,468,222 shares of Common Stock issuable upon exercise of Pre-Funded Warrants directly held by Fund II.Fairmount Funds Management LLC, SCHEDULE 13D, 2026-11-12
Purpose of Transaction (Item 4)
Vivo Opportunity Fund Holdings, L.P.
On May 19, 2026, the Issuer, Indigo Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of the Issuer (the "First Merger Sub"), Indigo Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Issuer (the "Second Merger Sub" and, together with First Merger Sub, the "Merger Subs"), and Mentari Therapeutics, Inc., a Delaware corporation ("Mentari"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, (i) the First Merger Sub will merge with and into Mentari, with Mentari surviving the merger as a wholly owned subsidiary of the Company (the "First Merger"), and (ii) immediately following the First Merger and as part of the same overall transaction as the First Merger, Mentari will merge with and into the Second Merger Sub, with the Second Merger Sub surviving such merger (the "Second Merger" and, together with the First Merger, the "Merger"). Subject to the terms and conditions of the Merger Agreement, at the effective time of the First Merger (the "First Effective Time"), each share of Mentari capital stock outstanding immediately prior to the First Effective Time will be converted into the right to receive a number of the Issuer's common shares (the "Common Shares") equal to the exchange ratio determined under the Merger Agreement (the "Exchange …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-10; the filing has the rest
Fairmount Funds Management LLC
The Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of November 6, 2026. The Reporting Persons' securities include 10,555,507 shares of Common Stock directly held by Fund II, and exclude (i) 4,013,000 shares of Common Stock issuable upon conversion of 4,013 shares of Series A Preferred Stock directly held by Fund II and (ii) 1,468,222 shares of Common Stock issuable upon exercise of Pre-Funded Warrants directly held by Fund II. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock and the conversion of the Series A Preferred Stock is subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock. The securities exclude shares of Common Stock issuable upon exercise of Pre-Funded Warrants and conversion of Series A Preferred Stock in excess of such beneficial ownership limitations. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the outstanding shares of Common Stock, the beneficial ownership limitation with respect to the Series A Preferred Stock will automatically reduce to 9.99%. Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, at any time and …The first part of Item 4 of the SCHEDULE 13D filed 2026-11-12; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-20 | Sabby Management, LLC | 9.9% | SCHEDULE 13G |
| 2026-05-27 | Squadron Master Fund LP | 9.8% | SCHEDULE 13G |
| 2026-06-05 | ADAR1 Capital Management, LLC | 24.1% | SCHEDULE 13G |
| 2026-06-10 | Vivo Opportunity Fund Holdings, L.P. | 21.7% | SCHEDULE 13D |
| 2026-08-14 | Ikarian Capital, LLC | 4.2% | SCHEDULE 13G |
| 2026-10-07 | ADAR1 Capital Management, LLC | 17.2% | SCHEDULE 13G/A |
| 2026-11-12 | Fairmount Funds Management LLC | 19.99% | SCHEDULE 13D |
| 2026-11-13 | Deep Track Capital, LP | 5.64% | SCHEDULE 13G |
| 2026-11-13 | Commodore Capital LP | 5.6% | SCHEDULE 13G |
Questions about who owns Mentari Therapeutics, Inc.
Who owns Mentari Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Mentari Therapeutics, Inc.: Vivo Opportunity Fund Holdings, L.P. (21.7%, Schedule 13D, filed 2026-06-10), Fairmount Funds Management LLC (19.99%, Schedule 13D, filed 2026-11-12), ADAR1 Capital Management, LLC (17.2%, Schedule 13G/A, filed 2026-10-07), Sabby Management, LLC (9.9%, Schedule 13G, filed 2026-01-20) and Squadron Master Fund LP (9.8%, Schedule 13G, filed 2026-05-27); 2 more are listed above.
Who are the largest shareholders of Mentari Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Mentari Therapeutics, Inc. on this page are Vivo Opportunity Fund Holdings, L.P. (21.7%), Fairmount Funds Management LLC (19.99%) and ADAR1 Capital Management, LLC (17.2%).
When did Vivo Opportunity Fund Holdings, L.P. buy into Mentari Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Vivo Opportunity Fund Holdings, L.P. on this page is the Schedule 13D, filed 2026-06-10, reporting 21.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Mentari Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Leadership change: Gregory Divis appointed, President and Chief Executive Officer, and 1 more | — | Leadership changes | Source |
| November 6, 2026 | Acquired Mentari | $490M | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for Mentari Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.
